Manzhan Zhang

Email: zhangmanzhan@163.com

Introduction: 
I was born in Zhejiang, China and I received BS degree from  East China University of Science and Technology in 2020. I'm currently a PhD graduatein the research group of Professor Li at East China University of Science and Technology and major in CADD/AIDD.

Education Background:
2020-2026, Ph.D student , Pharmacy, East China University of Science and Technology.  
2016-2020, Bachelor of Science, Pharmaceutical Preparation, East China University of Science and Technology.

Publication:

1. Manzhan Zhang^†, Yuxin Wan^†, Jing Wang, Shiliang Li*, Honglin Li*.. Artificial Intelligence and Computational Methods in Human Metabolism Research: A Comprehensive Survey.Journal of Pharmaceutical Analysis, 2025. 15(8): 101437
2. Huan He^†, Manzhan Zhang^†, Xiaoxiao Yang^†, Shuai He^†, Xiayu Shi, Feng Hu, Chang Liu, Xingsen Zhang, Na Chen, Xiaoqian Zhu, Leihao Zhang, Tianyu Ye, Rong Zhang, Yanru Yang, Rui Wang, Zhenjiang Zhao, Zhuo Chen, Xuhong Qian, Honglin Li, Zhe Wang*, Kai Zhang*, Kangdong Liu*, Shiliang Li*. Contrastive Learning-Enhanced Drug Metabolite Prediction Drives the Discovery of an Orally Bioavailable RSK4 Inhibitor for Esophageal Cancer. bioRxiv, 2025.
3. Caolin Wang^†, Yiting Cen^†, Manzhan Zhang^†, Jiahong Tang, Zitong Yan, Lijuan Xie, Deheng Sun, Wei Zhou, Jie Wang, Panpan Yu, Zhen Yuan, Junyi Wang, Zeyan Hu, Tingyuan Yang, Wenjie Sha, Shiliang Li, Zhenjiang Zhao*, Yufang Xu*, Zhuo Chen*, Honglin Li*. Design and Development of Novel EGFR Inhibitors Spanning All Subgroups of EGFR Mutations in Non-small Cell Lung Cancer. The Innovation, 2026, 101313
4. Rong Zhang^†, Tao Yu^†, Manzhan Zhang^†, Jiatong Li, Ao Gu, Muerzhate Aimaiti, Shiliang Li, Huan He*, Yingbin Liu*, Honglin Li*. Discovery of Potent and Selective Pyrrolo[2,3-d]Pyrimidine-Based Aurora A Inhibitors with Demonstrated Efficacy against Patient-Derived Gastric Cancer Organoids. Journal of Medicinal Chemistry, 2025. 68(18): 19607-19625
5. Limin Leng^†, Shuai He^†, Manzhan Zhang^†, Yanru Yang, Yuanyuan Ge, Yuan Yuan, Qiqi Niu, Xiayu Shi, Zhuo Chen, Zhenjiang Zhao, Huan He, Honglin Li, Yufang Xu*, Zhe Wang*, Shiliang Li*. Design and Structural Optimization of Orally Bioavailable RSK4 Inhibitors for the Treatment of Esophageal Squamous Cell Carcinoma. Journal of Medicinal Chemistry, 2026. 69 (1): 368-386
6. Zhen Yuan^†, Manzhan Zhang^†, Longfeng Chang^†, Xingyu Chen, Shanshan Ruan, Shanshan Shi, Yiqing Zhang, Lili Zhu*, Honglin Li*, Shiliang Li*. Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation. J. Mol. Model., 2024. 30 : 131
7. Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, Honglin Li*, Song Wu*, Yang Du*. G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders. Signal Transduct. Target. Ther., 2023. 8 : 177